CD274 and endometrial cancer: The MMRd-GREEN trial is a phase III trial in which women with stage II LVSI or stage III MMRd endometrial cancer are randomized to adjuvant pelvic radiotherapy combined with and followed by the PD-L1 inhibitor durvalumab (13 cycles of 1500 mg intravenously, every 4 weeks) for one year or radiotherapy alone.